Steven W. Pipe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Steven W. Pipe has a total of 434 co-authors. Here are the top co-authors by number of shared publications:
- Flora Peyvandi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
12 shared publications - Johnny Mahlangu
University of the Witwatersrand
11 shared publications - Guy Young
Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, United States
10 shared publications - Wolfgang Miesbach
University Hospital Frankfurt, Frankfurt, Germany
9 shared publications - Glenn F. Pierce
World Federation of Hemophilia
8 shared publications Michaela Lehle
Product Development Clinical Science, Oncology & Haematology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
8 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Haemnet Ltd in Bleeding Disorders Care & Practice
- Vol. 13 (1) , 38
Use of eptacog beta for perioperative haemostatic management in major surgery in people with haemophilia A and inhibitors receiving emicizumab prophylaxis: A US case series
Introduction: Bypassing agents are required for bleed management in people with haemophilia A and inhibitors (PwHAI) undergoing major surgery, including patients on prophylaxis. In the setting of prophylaxis with emicizumab, recombinant activated factor VII (rFVIIa) is the preferred bleed treatment class for these patients. Eptacog beta is the newest addition in the rFVIIa product class in the US and is approved in the surgical setting in the EU. The aim of this report is to describe the safety, effectiveness, and real-world use of eptacog beta for perioperative bleed control during major surgery in PwHAI in the US using emicizumab prophylaxis. Methods: This is a retrospective case series describing eight PwHAI on emicizumab prophylaxis who used eptacog beta for perioperative bleed control during major surgery (six arthroplasties, one radical nephrectomy, and one transforaminal lumbar interbody fusion) from five centres in the US. Patient characteristics, medical history, perioperative eptacog beta usage, intraoperative surgical and haemostatic outcomes, and postoperative outcomes are described. Results: All participants achieved haemostatic control with eptacog beta during major surgery using doses ranging from 70 to 225 µg/kg (median: 76.9 µg/kg). A median of 17 doses (range: 9–77) was used per participant. Participants were treated for a median of 5.75 days (range: 2–29). One case included intraoperative tranexamic acid and thrombin. Four individuals were switched to other haemostatic agents postoperatively due to lack of sufficient eptacog beta stock in the hospital pharmacy. Three participants received eptacog beta for the entirety of the postoperative period. One participant received eptacog alfa pre- and intraoperatively and switched to eptacog beta in the postoperative period. Intraoperatively, there were no adverse bleeding events and no need for transfusions. Postoperatively, there were no bleeds, thromboembolic events, or hospital readmission within 30 days due to bleeding or thrombosis. Conclusions: Eptacog beta provided adequate haemostatic control during and after major surgical procedures in PwHAI who were on prophylaxis with emicizumab, with no safety signals observed.
- 20 October 2026
- Published by Haemnet Ltd in Bleeding Disorders Care & Practice
- Vol. 13 (1) , 38
Open AccessUse of eptacog beta for perioperative haemostatic management in major surgery in people with haemophilia A and inhibitors receiving emicizumab prophylaxis: A US case series
Introduction: Bypassing agents are required for bleed management in people with haemophilia A and inhibitors (PwHAI) undergoing major surgery, including patients on prophylaxis. In the setting of prophylaxis with emicizumab, recombinant activated factor VII (rFVIIa) is the preferred bleed treatment class for these patients. Eptacog beta is the newest addition in the rFVIIa product class in the US and is approved in the surgical setting in the EU. The aim of this report is to describe the safety, effectiveness, and real-world use of eptacog beta for perioperative bleed control during major surgery in PwHAI in the US using emicizumab prophylaxis. Methods: This is a retrospective case series describing eight PwHAI on emicizumab prophylaxis who used eptacog beta for perioperative bleed control during major surgery (six arthroplasties, one radical nephrectomy, and one transforaminal lumbar interbody fusion) from five centres in the US. Patient characteristics, medical history, perioperative eptacog beta usage, intraoperative surgical and haemostatic outcomes, and postoperative outcomes are described. Results: All participants achieved haemostatic control with eptacog beta during major surgery using doses ranging from 70 to 225 µg/kg (median: 76.9 µg/kg). A median of 17 doses (range: 9–77) was used per participant. Participants were treated for a median of 5.75 days (range: 2–29). One case included intraoperative tranexamic acid and thrombin. Four individuals were switched to other haemostatic agents postoperatively due to lack of sufficient eptacog beta stock in the hospital pharmacy. Three participants received eptacog beta for the entirety of the postoperative period. One participant received eptacog alfa pre- and intraoperatively and switched to eptacog beta in the postoperative period. Intraoperatively, there were no adverse bleeding events and no need for transfusions. Postoperatively, there were no bleeds, thromboembolic events, or hospital readmission within 30 days due to bleeding or thrombosis. Conclusions: Eptacog beta provided adequate haemostatic control during and after major surgical procedures in PwHAI who were on prophylaxis with emicizumab, with no safety signals observed.
- 7 June 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (8) , 1781-1782
Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents
Despite major advances in hemophilia care, many patients continue to experience breakthrough bleeding, progressive joint morbidity, inhibitor development, and substantial treatment burden. To help more individuals achieve active, unrestricted lives, health care professionals must move beyond traditional prophylaxis targets by applying evolving evidence on factor VIII (FVIII) levels, optimizing prophylaxis to provide sustained bleed protection, and individualizing therapy to meet patients' needs, preferences, and real‐world considerations. This 3‐segment podcast features expert discussions on optimizing joint health across the lifespan, including subclinical bleeding and imaging‐based monitoring; applying current and emerging guidance on FVIII targets and factor‐based strategies; and integrating rebalancing agents into practice, with a focus on clinical outcomes, safety and risk mitigation, treatment burden, patient selection, and individualized hemophilia management. To view this activity and obtain CME/CE credit, visit http://www.cmeologyce.org/ajhhemophiliapodcast .
- 7 June 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (8) , 1781-1782
Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents
Despite major advances in hemophilia care, many patients continue to experience breakthrough bleeding, progressive joint morbidity, inhibitor development, and substantial treatment burden. To help more individuals achieve active, unrestricted lives, health care professionals must move beyond traditional prophylaxis targets by applying evolving evidence on factor VIII (FVIII) levels, optimizing prophylaxis to provide sustained bleed protection, and individualizing therapy to meet patients' needs, preferences, and real‐world considerations. This 3‐segment podcast features expert discussions on optimizing joint health across the lifespan, including subclinical bleeding and imaging‐based monitoring; applying current and emerging guidance on FVIII targets and factor‐based strategies; and integrating rebalancing agents into practice, with a focus on clinical outcomes, safety and risk mitigation, treatment burden, patient selection, and individualized hemophilia management. To view this activity and obtain CME/CE credit, visit http://www.cmeologyce.org/ajhhemophiliapodcast .
- 21 January 2026
- Published by Clinical Care Targeted Communications Group, LLC in The American Journal of Managed Care
- Vol. 32 (Suppl 2) , S15-S24
Redefining hemophilia management: treatment goals, nonfactor replacement therapies, and the role of fitusiran
Hemophilia is a rare, but debilitating congenital bleeding disorder. Current therapeutic guidelines, last updated in 2020, recommend recombinant clotting factor concentrates as the standard replacement therapy, with emicizumab offered as an alternative nonfactor standard of care. Since the publication of those guidelines, approvals of new gene-based and nonfactor therapies have reshaped the therapeutic landscape. This supplement describes the safety and efficacy of those therapies approved after the 2020 guidelines were published. It also presents managed care considerations describing how opportunities for resource optimization, therapeutic efficiency, and alternative administration approaches may advance progress toward aspirational treatment goals. A main focus is on fitusiran, the most recently approved nonfactor therapy, which introduced a novel mechanism of action and dosing strategy to the hemophilia therapeutic landscape in addition to its broad patient applicability. As this and other therapeutic advancements redefine the standard of care for patients with hemophilia, managed care and policy frameworks must adapt to ensure timely access and affordability. Likewise, updates to clinical guidelines and care pathways are essential to capture the rapidly evolving therapeutic landscape.
- 21 January 2026
- Published by Clinical Care Targeted Communications Group, LLC in The American Journal of Managed Care
- Vol. 32 (Suppl 2) , S15-S24
Redefining hemophilia management: treatment goals, nonfactor replacement therapies, and the role of fitusiran
Hemophilia is a rare, but debilitating congenital bleeding disorder. Current therapeutic guidelines, last updated in 2020, recommend recombinant clotting factor concentrates as the standard replacement therapy, with emicizumab offered as an alternative nonfactor standard of care. Since the publication of those guidelines, approvals of new gene-based and nonfactor therapies have reshaped the therapeutic landscape. This supplement describes the safety and efficacy of those therapies approved after the 2020 guidelines were published. It also presents managed care considerations describing how opportunities for resource optimization, therapeutic efficiency, and alternative administration approaches may advance progress toward aspirational treatment goals. A main focus is on fitusiran, the most recently approved nonfactor therapy, which introduced a novel mechanism of action and dosing strategy to the hemophilia therapeutic landscape in addition to its broad patient applicability. As this and other therapeutic advancements redefine the standard of care for patients with hemophilia, managed care and policy frameworks must adapt to ensure timely access and affordability. Likewise, updates to clinical guidelines and care pathways are essential to capture the rapidly evolving therapeutic landscape.
- Open Access
- 27 October 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (2) , 747-765
A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy
- 27 October 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (2) , 747-765
Open AccessA comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy
- 25 October 2025
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 20-54
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025
- 25 October 2025
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 20-54
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025
- Top Cited PapersOpen Access
- 11 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3543-3552
Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
Etranacogene dezaparvovec (CSL222, formerly AMT-061) is a recombinant adeno-associated virus serotype 5 (AAV5) vector containing the highly active factor IX (FIX) Padua variant controlled by a liver-specific promoter. This phase 2b, open-label, single-dose, single-arm, multicenter trial evaluated the efficacy and safety of etranacogene dezaparvovec. Three adult participants with severe or moderately severe hemophilia B (FIX ≤2%) and AAV5-neutralizing antibodies received a single IV dose (2 × 1013 genome copies per kg) of etranacogene dezaparvovec. The primary end point of FIX activity ≥5 IU/dL at 6 weeks was met (mean, 30.6 IU/dL). Secondary end points included bleed frequency, FIX concentrate use, and adverse events. Here, we report the end-of-study 5-year outcomes. After administration, mean (range) FIX activity increased to 40.8 IU/dL (31.3-50.2) at year 1 and was maintained at 45.7 IU/dL (39.0-51.2) at year 5. Mean annualized bleeding rate (all bleeds) was 0.14 for the cumulative follow-up period years 0 to 5. Two participants had 5 bleed-free years after treatment. Per protocol, 1 participant received episodic FIX replacement therapy after treatment for elective surgeries, 2 bleeding episodes, and 2 single self-administered infusions for unreported reasons. All participants discontinued and remained free of FIX prophylaxis. During the 5-year study period, there were no clinically significant elevations in liver enzymes, requirement for steroids, FIX inhibitor development, thrombotic complications, or late-emergent safety events in any participant. Five years after administration, etranacogene dezaparvovec was effective in adults with hemophilia B with a favorable safety profile. Participants are eligible to participate in an extension study (ClinicalTrials.gov identifier: NCT05962398) for 10-year additional follow-up. This trial was registered at www.clinicaltrials.gov as #NCT03489291.
- 11 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3543-3552
Top Cited PapersOpen AccessCompletion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
Etranacogene dezaparvovec (CSL222, formerly AMT-061) is a recombinant adeno-associated virus serotype 5 (AAV5) vector containing the highly active factor IX (FIX) Padua variant controlled by a liver-specific promoter. This phase 2b, open-label, single-dose, single-arm, multicenter trial evaluated the efficacy and safety of etranacogene dezaparvovec. Three adult participants with severe or moderately severe hemophilia B (FIX ≤2%) and AAV5-neutralizing antibodies received a single IV dose (2 × 1013 genome copies per kg) of etranacogene dezaparvovec. The primary end point of FIX activity ≥5 IU/dL at 6 weeks was met (mean, 30.6 IU/dL). Secondary end points included bleed frequency, FIX concentrate use, and adverse events. Here, we report the end-of-study 5-year outcomes. After administration, mean (range) FIX activity increased to 40.8 IU/dL (31.3-50.2) at year 1 and was maintained at 45.7 IU/dL (39.0-51.2) at year 5. Mean annualized bleeding rate (all bleeds) was 0.14 for the cumulative follow-up period years 0 to 5. Two participants had 5 bleed-free years after treatment. Per protocol, 1 participant received episodic FIX replacement therapy after treatment for elective surgeries, 2 bleeding episodes, and 2 single self-administered infusions for unreported reasons. All participants discontinued and remained free of FIX prophylaxis. During the 5-year study period, there were no clinically significant elevations in liver enzymes, requirement for steroids, FIX inhibitor development, thrombotic complications, or late-emergent safety events in any participant. Five years after administration, etranacogene dezaparvovec was effective in adults with hemophilia B with a favorable safety profile. Participants are eligible to participate in an extension study (ClinicalTrials.gov identifier: NCT05962398) for 10-year additional follow-up. This trial was registered at www.clinicaltrials.gov as #NCT03489291.
- 19 June 2025
- Published by Wiley in Haemophilia
- Vol. 31 (4) , 713-721
Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors
Introduction: Joint and muscle bleeding in persons with haemophilia (PwH) causes acute pain, an important patient‐reported outcome for evaluating treatment response. Eptacog beta is a recombinant activated human FVII bypassing agent approved for the treatment and control of bleeding in PwH A or B with inhibitors (PwHABI) ≥12 years using initial dose regimens (IDRs) of 75 or 225 µg/kg. Aim: To evaluate pain reduction in PwHABI who treated bleeding episodes (BEs) with eptacog beta during the PERSEPT 1 trial. Methods: PwHABI were randomly assigned to 75 or 225 µg/kg IDRs for BE treatment. Participants reported pain levels at predefined treatment evaluation timepoints using a visual analogue scale (VAS). Pain analyses were stratified by age, IDR assignment, and baseline pain levels. The diagnostic potential for using VAS pain score reductions to assess treatment response was explored using receiver operating characteristic (ROC) analysis. Results: Five adolescents and 22 adults treated 468 BEs. Mean VAS scores decreased 30%–58% from baseline at 3 h post‐initial eptacog beta infusion amongst age and IDR categories, with further VAS score reductions observed through 24 h. PwHABI with high baseline BE pain showed larger absolute VAS score reductions before ending treatment than PwHABI experiencing mild BE pain. The optimum VAS score percentage reduction cutoff for predicting treatment outcomes was 44%. Conclusion: Pain relief over 24 h was observed with eptacog beta treatment across IDR and age categories. This post hoc study demonstrates that percentage reduction from baseline VAS score influences perception of bleed resolution and can predict treatment outcomes.
- 19 June 2025
- Published by Wiley in Haemophilia
- Vol. 31 (4) , 713-721
Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by Inhibitors
Introduction: Joint and muscle bleeding in persons with haemophilia (PwH) causes acute pain, an important patient‐reported outcome for evaluating treatment response. Eptacog beta is a recombinant activated human FVII bypassing agent approved for the treatment and control of bleeding in PwH A or B with inhibitors (PwHABI) ≥12 years using initial dose regimens (IDRs) of 75 or 225 µg/kg. Aim: To evaluate pain reduction in PwHABI who treated bleeding episodes (BEs) with eptacog beta during the PERSEPT 1 trial. Methods: PwHABI were randomly assigned to 75 or 225 µg/kg IDRs for BE treatment. Participants reported pain levels at predefined treatment evaluation timepoints using a visual analogue scale (VAS). Pain analyses were stratified by age, IDR assignment, and baseline pain levels. The diagnostic potential for using VAS pain score reductions to assess treatment response was explored using receiver operating characteristic (ROC) analysis. Results: Five adolescents and 22 adults treated 468 BEs. Mean VAS scores decreased 30%–58% from baseline at 3 h post‐initial eptacog beta infusion amongst age and IDR categories, with further VAS score reductions observed through 24 h. PwHABI with high baseline BE pain showed larger absolute VAS score reductions before ending treatment than PwHABI experiencing mild BE pain. The optimum VAS score percentage reduction cutoff for predicting treatment outcomes was 44%. Conclusion: Pain relief over 24 h was observed with eptacog beta treatment across IDR and age categories. This post hoc study demonstrates that percentage reduction from baseline VAS score influences perception of bleed resolution and can predict treatment outcomes.
- Top Cited PapersOpen Access
- 19 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (25) , 2966-2977
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia. This phase 3 open-label extension study (ATLAS-OLE) evaluated safety and efficacy of an AT-based dose regimen (AT-DR) in males aged ≥12 years with severe hemophilia A/B, with/without inhibitors. The original dose regimen (ODR) of 80 mg monthly was optimized to AT-DR targeting AT activity levels 15% to 35% to mitigate thrombotic risk (starting dose of 50 mg once every 2 months, individually adjusted to 20 mg once every 2 months, or 20/50/80 mg monthly as needed). Primary and secondary end points were safety and efficacy, respectively. Integrated safety analyses assessed safety of AT-DR and ODR across all fitusiran studies and integrated efficacy analyses compared efficacy of AT-DR in ATLAS-OLE with phase 3 parent study control groups. At interim data cutoff, 213 participants were enrolled on AT-DR (78% on regimens of once every 2 months). Integrated safety analyses of participants receiving AT-DR (n = 286) demonstrated that AT-DR was well tolerated. In ATLAS-OLE, median observed annualized bleeding rate (ABR) with AT-DR was 3.7 (interquartile range, 0.0-7.5). Integrated efficacy analyses demonstrated superiority of AT-DR over on-demand clotting factor concentrates (CFCs; 71% mean ABR reduction; P < .0001), and on-demand bypassing agents (BPAs; 73% mean ABR reduction; P = .0006); improvement over BPA prophylaxis (70% mean ABR reduction); and ABR comparable with that observed with CFC prophylaxis. Fitusiran AT-DR was well tolerated and maintained bleed protection with as few as 6 injections per year. This trial was registered at www.ClinicalTrials.gov as #NCT03754790.
- 19 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (25) , 2966-2977
Top Cited PapersOpen AccessSafety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia. This phase 3 open-label extension study (ATLAS-OLE) evaluated safety and efficacy of an AT-based dose regimen (AT-DR) in males aged ≥12 years with severe hemophilia A/B, with/without inhibitors. The original dose regimen (ODR) of 80 mg monthly was optimized to AT-DR targeting AT activity levels 15% to 35% to mitigate thrombotic risk (starting dose of 50 mg once every 2 months, individually adjusted to 20 mg once every 2 months, or 20/50/80 mg monthly as needed). Primary and secondary end points were safety and efficacy, respectively. Integrated safety analyses assessed safety of AT-DR and ODR across all fitusiran studies and integrated efficacy analyses compared efficacy of AT-DR in ATLAS-OLE with phase 3 parent study control groups. At interim data cutoff, 213 participants were enrolled on AT-DR (78% on regimens of once every 2 months). Integrated safety analyses of participants receiving AT-DR (n = 286) demonstrated that AT-DR was well tolerated. In ATLAS-OLE, median observed annualized bleeding rate (ABR) with AT-DR was 3.7 (interquartile range, 0.0-7.5). Integrated efficacy analyses demonstrated superiority of AT-DR over on-demand clotting factor concentrates (CFCs; 71% mean ABR reduction; P < .0001), and on-demand bypassing agents (BPAs; 73% mean ABR reduction; P = .0006); improvement over BPA prophylaxis (70% mean ABR reduction); and ABR comparable with that observed with CFC prophylaxis. Fitusiran AT-DR was well tolerated and maintained bleed protection with as few as 6 injections per year. This trial was registered at www.ClinicalTrials.gov as #NCT03754790.
- Open Access
- 13 June 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (12) , 2980-2987
Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies
Hemophilia B is a rare, X-linked bleeding disorder that predominantly affects males and is caused by factor IX (FIX) gene variants, leading to spontaneous bleeding and impaired ability to clot after injury or surgeries. Standard of care is prophylaxis to increase FIX levels. DTX101 is a nonreplicating adeno-associated viral serotype rh10 gene transfer vector containing a codon-optimized wild-type human FIX coding sequence. The phase 1/2 open-label, single-arm, multicenter, dose-finding 101HEMB01 study examined the safety/efficacy of DTX101 in adult males with hemophilia B; the 101HEMB02 follow-up study assessed long-term outcomes. Participants received DTX101 as 1.6 × 1012 (cohort 1; n = 3) or 5.0 × 1012 genome copies/kg (cohort 2; n = 3) at baseline and were monitored through week 44 (cohort 2) or 52 (cohort 1) in 101HEMB01, and 4 additional years in 101HEMB02. The primary end point of 101HEMB01, peak plasma FIX level at week 6, showed median levels of 7.0 (range, 5.0-8.0) and 10.0 IU/dL (range, 6.0-16.0) in cohorts 1 and 2, respectively. Levels failed to reach the 20 IU/dL target criteria; all participants required adjunct FIX replacement therapy based on low FIX activity at intermediate time points. In 101HEMB01, 4 of 6 participants experienced treatment-related adverse events of elevated transaminase levels (n = 3) and fatigue (n = 1), and 1 experienced fatigue in 101HEMB02; none experienced related serious adverse events. Elevated transaminase levels were asymptomatic and resolved with steroids in all participants. The DTX101 program was halted for insufficient treatment response; however, from its completion, lessons can be learned regarding the design and execution of gene therapy clinical trials, including additional optimization of transgene sequence and immunosuppression protocols. The 101HEMB01 and 101HEMB02 studies were registered at www.ClinicalTrials.gov as #NCT02618915 and #NCT02971969, respectively.
- 13 June 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (12) , 2980-2987
Open AccessGene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies
Hemophilia B is a rare, X-linked bleeding disorder that predominantly affects males and is caused by factor IX (FIX) gene variants, leading to spontaneous bleeding and impaired ability to clot after injury or surgeries. Standard of care is prophylaxis to increase FIX levels. DTX101 is a nonreplicating adeno-associated viral serotype rh10 gene transfer vector containing a codon-optimized wild-type human FIX coding sequence. The phase 1/2 open-label, single-arm, multicenter, dose-finding 101HEMB01 study examined the safety/efficacy of DTX101 in adult males with hemophilia B; the 101HEMB02 follow-up study assessed long-term outcomes. Participants received DTX101 as 1.6 × 1012 (cohort 1; n = 3) or 5.0 × 1012 genome copies/kg (cohort 2; n = 3) at baseline and were monitored through week 44 (cohort 2) or 52 (cohort 1) in 101HEMB01, and 4 additional years in 101HEMB02. The primary end point of 101HEMB01, peak plasma FIX level at week 6, showed median levels of 7.0 (range, 5.0-8.0) and 10.0 IU/dL (range, 6.0-16.0) in cohorts 1 and 2, respectively. Levels failed to reach the 20 IU/dL target criteria; all participants required adjunct FIX replacement therapy based on low FIX activity at intermediate time points. In 101HEMB01, 4 of 6 participants experienced treatment-related adverse events of elevated transaminase levels (n = 3) and fatigue (n = 1), and 1 experienced fatigue in 101HEMB02; none experienced related serious adverse events. Elevated transaminase levels were asymptomatic and resolved with steroids in all participants. The DTX101 program was halted for insufficient treatment response; however, from its completion, lessons can be learned regarding the design and execution of gene therapy clinical trials, including additional optimization of transgene sequence and immunosuppression protocols. The 101HEMB01 and 101HEMB02 studies were registered at www.ClinicalTrials.gov as #NCT02618915 and #NCT02971969, respectively.
- Open Access
- 2 May 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4) , 102879
Guidelines for management of hemophilia—why, what, and how?
- 2 May 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4) , 102879
Open AccessGuidelines for management of hemophilia—why, what, and how?